We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-5.44%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.92B
AUM Growth
-$82.3M
Cap. Flow
-$215M
Cap. Flow %
-11.22%
Top 10 Hldgs %
52.67%
Holding
387
New
94
Increased
95
Reduced
80
Closed
99

Sector Composition

Rank Sector Weight
1 Healthcare 12.85%
2 Industrials 0.12%
3 Consumer Staples 0.07%
4 Consumer Discretionary 0.06%
5 Technology 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ABBV icon
26
PUT
AbbVie
ABBV
$465B
$14.5M 0.76%
2,347
+801
+52% +$48.8K
SHPG
27
CALL
DELISTED
Shire pic
SHPG
$12.8M 0.67%
+698
New +$126K
SHPG
28
PUT
DELISTED
Shire pic
SHPG
$12.8M 0.67%
+698
New +$126K
GLD icon
29
CALL
SPDR Gold Trust
GLD
$131B
$12.7M 0.66%
+1,000
New +$120K
MDCO
30
CALL
DELISTED
Medicines Co
MDCO
$12.2M 0.63%
3,614
-5,887
-62% -$208K
VTRS icon
31
CALL
Viatris
VTRS
$20.8B
$12.1M 0.63%
2,804
+2,500
+822% +$111K
SAGE
32
CALL
DELISTED
Sage Therapeutics
SAGE
$12.1M 0.63%
4,009
+3,716
+1,268% +$124K
SAGE
33
PUT
DELISTED
Sage Therapeutics
SAGE
$10.5M 0.55%
+3,496
New +$117K
ABT icon
34
Abbott
ABT
$187B
$10.4M 0.54%
+264,700
New +$10.5M
XNTK icon
35
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
$10.1M 0.52%
1,858
-3,479
-65% -$183K
DXCM icon
36
CALL
DexCom
DXCM
$28.9B
$9.36M 0.49%
+4,720
New +$80.4K
DVAX
37
PUT
DELISTED
Dynavax Technologies
DVAX
$8.66M 0.45%
5,942
+5,337
+882% +$91.2K
TVTX icon
38
PUT
Travere Therapeutics
TVTX
$5.2B
$8.6M 0.45%
4,826
-1,425
-23% -$23.1K
IONS icon
39
CALL
Ionis Pharmaceuticals
IONS
$9.14B
$8.38M 0.44%
+3,600
New +$116K
ALKS icon
40
CALL
Alkermes
ALKS
$8.47B
$7.93M 0.41%
+1,335
New +$55.1K
LXRX icon
41
CALL
Lexicon Pharmaceuticals
LXRX
$1.04B
$7.63M 0.4%
5,320
+1,228
+30% +$16.7K
NVAX icon
42
PUT
Novavax
NVAX
$1.21B
$7.59M 0.4%
522
+478
+1,086% +$54.8K
OTLK icon
43
Outlook Therapeutics
OTLK
$169M
$7.04M 0.37%
+12,931
New +$7.71M
CELG
44
CALL
DELISTED
Celgene Corp
CELG
$6.86M 0.36%
695
+382
+122% +$39.5K
TENX icon
45
Tenax Therapeutics
TENX
$419M
$6.67M 0.35%
81
-6
-7% -$501K
IOVA icon
46
PUT
Iovance Biotherapeutics
IOVA
$2.1B
$6.1M 0.32%
+7,526
New +$47.3K
BPTH
47
DELISTED
Bio-Path Holdings Inc
BPTH
$5.95M 0.31%
+747
New +$7.56M
ITCI
48
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.7M 0.3%
1,467
+259
+21% +$9.31K
VXZ
49
CALL
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
$5.49M 0.29%
993
+873
+728% +$38.4K
ALNY icon
50
CALL
Alnylam Pharmaceuticals
ALNY
$38.5B
$5.48M 0.29%
+987
New +$62.2K

Similar funds

Sabby Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sabby Management held 387 positions worth $1.92B, down 4.1% from $2B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $215M in Q2 2016, closing 99 positions and reducing 80 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 12% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Abbott worth $10.4M.

  • Sabby Management's largest Q2 2016 buy was Abbott: 264,700 shares worth $10.4M.
  • Sabby Management added most to Regeneron Pharmaceuticals in Q2 2016, an estimated $12.5M increase.
  • Sabby Management's biggest Q2 2016 reduction was Biogen, cutting an estimated $7.14M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2016, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.92B portfolio in Q2 2016.
  • Sabby Management opened 94 new positions and closed 99 in Q2 2016.
  • Sabby Management's portfolio value fell 4.1% quarter-over-quarter to $1.92B.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.